Horst & Graben Wealth Management’s Citius Pharmaceuticals CTXR Stock Holding History

Horst & Graben Wealth Management’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,029	Closed	-$37.9K	–	160
2024 Q3	$37.9K	Hold	3,029	–	–	0.01%	154
2024 Q2	$44.2K	Hold	3,029	–	–	0.01%	151
2024 Q1	$67.9K	Hold	3,029	–	–	0.01%	144
2023 Q4	$57.3K	Hold	3,029	–	–	0.01%	136
2023 Q3	$51.8K	Hold	3,029	–	–	0.01%	134
2023 Q2	$91K	Hold	3,029	–	–	0.02%	130
2023 Q1	$89K	Buy	+3,029	New	+$87.3K	0.02%	130
2022 Q4	–	Sell	-3,029	Closed	-$92K	–	127
2022 Q3	$92K	Hold	3,029	–	–	0.03%	123
2022 Q2	$70K	Hold	3,029	–	–	0.02%	131
2022 Q1	$136K	Hold	3,029	–	–	0.03%	134
2021 Q4	$117K	Hold	3,029	–	–	0.03%	133
2021 Q3	$154K	Hold	3,029	–	–	0.04%	133
2021 Q2	$264K	Buy	3,029 +1,045	+53%	+$62.8K	0.07%	108
2021 Q1	$88K	Buy	+1,984	New	+$79K	0.03%	128

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Horst & Graben Wealth Management's CTXR Position: Q4 2024 in Review

Horst & Graben Wealth Management sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 3,029 shares — an estimated $37.9K sold.

Horst & Graben Wealth Management first reported a position in CTXR in Q1 2021 and held it in 14 quarters. The position peaked at $264K in Q2 2021. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

Horst & Graben Wealth Management reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Horst & Graben Wealth Management sold 3,029 Citius Pharmaceuticals shares in Q4 2024, an estimated $37.9K.
Horst & Graben Wealth Management first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 14 quarters.
Horst & Graben Wealth Management's Citius Pharmaceuticals position peaked at $264K in Q2 2021.
30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Horst & Graben Wealth Management's 13F filing for Q4 2024, filed 24 Jan 2025.